Table 4.

Stratified Log-rank Analysis of the Impact of Convalescent Plasma Treatment on Time to Hospital Discharge as Compared to the Control Group

	All CP Recipients (n = 64) RR (95% CI)	AI ≥ 1.4a (n = 32) RR (95% CI)	AI ≥ 5b (n = 18) RR (95% CI)
Overall	1.28 (.91–1.81)	1.14 (.72–1.83)	1.63 (.92–2.88)
Stratification subgroups
Sex
Female	1.28 (.75–2.19)	1.31 (.66–2.60)	1.21 (.40–3.68)
Male	1.27 (.80–2.00)	1.00 (.52–1.91)	1.85 (.94–3.64)
Age group, y
18–49	.90 (.48–1.70)	1.77 (.70–4.48)	.81 (.29–2.29)
50–64	.82 (.43–1.55)	.80 (.37–1.75)	1.57 (.25–9.93)
≥ 65	1.86 (1.03–3.36)	1.28 (.58–2.85)	2.70 (1.16–6.28)
Race/ethnicity
Black or African American	1.49 (.56–3.93)	1.19 (.34–4.14)	3.00 (.67–13.4)
Hispanic or Latino	.88 (.51–1.54)	1.09 (.48–2.51)	.95 (.44–2.05)
Other/Unknown	1.38 (.54–3.51)	1.75 (.44–6.91)	1.20 (.14–10.5)
White or Caucasian	1.51 (.82–2.76)	1.05 (.52–2.14)	6.67 (1.39–32.1)
Baseline oxygen requirements
Low flow supplemental oxygen	1.34 (.89–2.03)	1.15 (.68–1.94)	2.03 (.90–4.56)
NIPPV or HFNC	1.52 (.78–2.96)	1.00 (.33–3.02)	2.36 (.97–5.74)
Days from symptom onset to admission
≤5	1.31 (.79–2.16)	1.03 (.52–2.04)	1.82 (.66–5.06)
>5	1.16 (.71–1.89)	1.21 (.63–2.35)	1.30 (.64–2.65)
Remdesivir use
No	1.20 (.79–1.82)	1.04 (.60–1.78)	1.66 (.83–3.33)
Yes	1.41 (.75–2.66)	1.68 (.63–4.50)	1.37 (.50–3.77)
Corticosteroid use
No	1.25 (.81–1.93)	.97 (.52–1.83)	1.94 (.94–4.01)
Yes	1.66 (.90–3.05)	1.74 (.82–3.69)	1.66 (.63–4.37)

Abbreviations: AI, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibody index; CI, confidence interval; CP, convalescent plasma; HFNC, high-flow nasal cannula; NIPPV, noninvasive positive pressure ventilation; RR, rate ratio.

^aAt least 1 unit with AI ≥ 1.4, but not 2 units both with AI ≥ 5.

^bTwo units both with AI ≥ 5.